Current Portfolio

Companies

KannaHealth

Kanna Health is a clinical stage biopharmaceutical company developing novel therapeutics focused on men’s health and mental health conditions. They recently obtained regulatory clinical approvals (US IND, UK CTA) and have initiated Phase 1 human trials to assess the safety and pharmacokinetics of the lead product. Their lead product candidate, KH-001, is being developed as the first FDA-approved treatment for premature ejaculation, a condition that impacts up to 20% of men. Premature ejaculation has no FDA-approved therapies currently available.

KH-001 is a potent, selective, and rapid-acting serotonin transporter inhibitor intended for on-demand use prior to intercourse. In preclinical studies, KH-001 demonstrated dose-dependent efficacy in delaying ejaculation in a validated animal model, along with a favorable safety profile. Kanna Health has an open IND with the FDA and initiated first-in-human Phase 1 studies in November 2023. With FDA approval, KH-001 is estimated to have peak global sales potential of $2.5-4 billion per year.

In addition to KH-001 for premature ejaculation, Kanna Health is developing a pipeline of proprietary kanna alkaloid-based compounds for rapid-acting treatment of mood disorders like anxiety and depression.

The goal is to do for premature ejaculation what Viagra did to revolutionize erectile dysfunction treatment. The team of repeat founders are raising an insider-led, pre-Series A convertible note, that is already half-filled.